Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
Status:
Completed
Trial end date:
2000-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give HIV-positive patients
a combination of anti-HIV drugs (abacavir [ABC] plus efavirenz [EFV] plus didanosine [ddI])
with and without hydroxyurea (HU).
Phase:
Phase 4
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Abacavir Didanosine Efavirenz HIV Protease Inhibitors Hydroxyurea Protease Inhibitors